Adocia Logo

Adocia

ADOC | PA

Overview

Corporate Details

ISIN(s):
FR0011184241 (+1 more)
LEI:
969500ZL79KYH9PTYP78
Country:
France
Address:
115 AVENUE LACASSAGNE, 69003 LYON
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Adocia is a clinical-stage biotechnology company founded in 2005, specializing in the development of innovative treatments for metabolic diseases, primarily diabetes and obesity. The company leverages its proprietary technology platforms and strong intellectual property to create best-in-class therapies by developing novel formulations of already-approved peptides and proteins, including insulins and other metabolic hormones. Adocia's product pipeline ranges from these advanced formulations to immunoprotective scaffolds for cell therapies. Its business model focuses on out-licensing its products and technologies to partners after establishing clinical proof-of-concept in humans.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Adocia. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-07-11 11:18
Major Shareholding Notification
Franchissements de seuil
French 116.2 KB
2025-06-12 18:00
Declaration of Voting Results & Voting Rights Announcements
Inside Information / Other news releases
English 492.1 KB
2025-06-12 18:00
Declaration of Voting Results & Voting Rights Announcements
Informations privilégiées / Autres communiqués
French 491.7 KB
2025-05-22 18:00
Regulatory News Service
Inside Information / Other news releases
English 452.1 KB
2025-05-22 18:00
Regulatory News Service
Informations privilégiées / Autres communiqués
French 472.2 KB
2025-05-21 18:00
Pre-Annual General Meeting Information
Informations privilégiées / Autres communiqués
French 120.9 KB
2025-05-21 18:00
Pre-Annual General Meeting Information
Inside Information / Other news releases
English 130.5 KB
2025-05-15 18:00
Declaration of Voting Results & Voting Rights Announcements
Inside Information / Other news releases
English 474.1 KB
2025-05-15 18:00
Declaration of Voting Results & Voting Rights Announcements
Informations privilégiées / Autres communiqués
French 473.1 KB
2025-05-14 18:00
Earnings Release
Inside Information / News release on accounts, results
English 576.9 KB
2025-05-14 18:00
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
French 531.5 KB
2025-04-30 18:00
Registration Form
Inside Information / Other news releases
English 473.1 KB
2025-04-30 18:00
Registration Form
Informations privilégiées / Autres communiqués
French 461.0 KB
2025-04-29 16:29
Annual Report (ESEF)
Document d'Enregistrement Universel 2024
French 3.6 MB
2025-04-28 18:00
Regulatory News Service
Inside Information / Other news releases
English 692.6 KB

Automate Your Workflow. Get a real-time feed of all Adocia filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Adocia via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-03-21 N/A Other Buy 51,921 499,999.23 EUR
2024-03-21 N/A Other Buy 15,576 149,996.88 EUR
2023-12-29 N/A Other Sell 20,000 236,550.00 EUR
2023-10-05 N/A Other Sell 50,000 400,000.00 EUR
2023-09-20 N/A Other Sell 36,240 291,376.85 EUR
2023-07-28 N/A Other Buy 220,264 999,998.56 EUR
2023-07-28 N/A Other Buy 110 499.40 EUR

Peer Companies

Company Country Ticker View
Medicofarma Biotech Spolka Akcyjna Logo
Biotech R&D firm developing novel drugs, devices, and therapies with a focus on oncology.
Poland MDB
Medigene AG Logo
An immuno-oncology platform creating T cell receptor (TCR)-guided therapies to treat cancer.
Germany MDG1
MedinCell S.A. Logo
Develops and licenses long-acting injectable therapies using proprietary technology.
France MEDCL
Medivir Logo
Clinical-stage pharma firm developing tumor-directed therapies for high-need cancer patients.
Sweden MVIR
Mendus Logo
Developing immunotherapies using dendritic cells to prevent recurrence of AML & ovarian cancer.
Sweden IMMU
Merck KGaA Logo United States of America 6MK
Sweden MBOLIC
Milton Essex Spolka Akcyjna Logo
Develops AI-powered, non-invasive systems for allergy diagnostics & personalized medicine.
Poland MTN
Modus Therapeutics Holding AB Logo
Clinical-stage biotech developing sevuparin for sepsis, septic shock, and inflammation.
Sweden MODTX
Molecular Partners AG Logo
Pioneering DARPin protein drugs for complex diseases in oncology and virology.
Switzerland MOLN